Investor Presentaiton
Novo Nordisk Annual Report 2023
Introducing Novo Nordisk
Strategic Aspirations
Risks
Management
Consolidated statements
Additional information
ACCOUNTING POLICIES
Waste is measured as the sum of all the waste disposed of at production sites based
on weight receipts. Organic residues for recycling are waste from the production of
the active pharmaceutical ingredients, where the energy is recovered in biogas plants
and the digested slurry is used on local farmland as fertiliser. Ethanol is recovered in
internal regeneration plants and re-used. Energy recovery is waste disposed of at
waste-to-energy plants and at a biogas plant. Waste with no energy recovery covers
water waste and other waste not suitable for other disposal methods, such as
hazardous waste for incineration and various other types of waste.
7.5 Breaches of environmental regulatory limit values
In 2023 there were 12 breaches compared to 8 in 2022. None of the breaches resulted
in any correlated material negative impact on the environment. For all breaches,
mitigation actions are in progress.
ACCOUNTING POLICIES
Breaches of regulatory limit values cover all breaches with limit values reported to the
environmental authorities. Breaches related to the same continued exceedance at the
same site count as one breach for the year.
Section 8
Social performance
8.1 Patients reached with Novo Nordisk's
Diabetes and Obesity care products
Estimate in millions
2023
2022
2021
Patients reached with Novo Nordisk's
Diabetes care products
40.5
36.3
34.6
Patients reached with Novo Nordisk's
Obesity care products
1.1
0.6
0.3
Total number of patients reached
41.6
36.9
34.9
The estimated number of full-year patients reached with Novo Nordisk's Diabetes care
products increased from 36.3 million in 2022 to 40.5 million in 2023. The 12% increase
was primarily driven by the GLP-1 franchise, followed by the new-generation insulin
franchise and the human insulin franchise. The increase in number of full-year patients
reached with Novo Nordisk's Obesity care products in 2023 was primarily driven by the
continued launch of WegovyⓇ in new markets.
In 2023, the estimated number of full-year patients with diabetes reached with
Novo Nordisk's human insulin vials through the Access to Insulin Commitment was
2.4 million, compared to 1.8 million in 2022. The 33% growth through the Access to
Insulin Commitment was driven by increased sales through both government and
private market channels, sold at or below the USD 3 ceiling price. Novo Nordisk also
sold human insulin vials at or below the ceiling price of USD 3 in countries outside the
Commitment, reaching an estimated additional 2.6 million patients in 2023. This
represents a total of 5 million patients with diabetes reached with human insulin at
or below USD 3 per vial globally.
Through the Changing DiabetesⓇ in Children (CDIC) partnership, 52,249 children and
youth were reached in total by the end of 2023, compared to 41,033 by the end of 2022.
Almost half of the new enrolled children were reached through expansion in Asian
countries, mainly India, Pakistan, Indonesia and Vietnam. The children receive access to
diabetes care in clinics (e.g. patient education), as well as medical supplies if needed.
ACCOUNTING POLICIES
The number of full-year patients reached with Novo Nordisk's Diabetes and Obesity care
products, excluding devices, is estimated by dividing Novo Nordisk's annual sales volume
by the annual usage dose per patient for each product class, as defined by the WHO (for
Diabetes) and in accordance with the dose strength of the product (for Obesity).
The number of full-year patients reached with human insulin vials via the Novo
Nordisk Access to Insulin Commitment is estimated by dividing Novo Nordisk's annual
sales volume by the annual usage dose per patient reached via the Novo Nordisk
Access to Insulin Commitment, as defined by the WHO. The WHO-defined daily dosage
for these products may not accurately reflect the recommended or prescribed daily
dose. Actual doses are based on individual characteristics (e.g. age and weight) and
pharmacokinetic considerations. Despite this uncertainty, Novo Nordisk assesses this
to be the most consistent way of reporting.
The number of children reached with Diabetes care treatment through the Changing
Diabetes® in Children programme is measured as the total accumulated number of
children enrolled since the initiation of the partnership in 2009.
8.2 Employees
Number of employees
Number
Year-end employees (total)
Year-end number of full-time employees
2023
2022
64,319
63,370
55,185
54,393
2021
48,478
47,792
Employees by geographical area
Number
2023
2022
2021
International Operations
56,004
47,935
42,372
Denmark
28,692
22,916
19,150
EMEA (Europe, the Middle East and Africa),
excluding Denmark
8,808
7,954
7,530
6,485
6,148
5,833
12,019
10,917
9,859
8,315
7,250
6,106
64,319
55,185
48,478
China (Mainland China, Hong Kong, Taiwan)
Rest of World (all other countries)
North America Operations
Year-end employees (total)
90View entire presentation